Immutep to Participate in Upcoming Investor Conferences

GlobeNewswire

04-02

new logo.jpg

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:


Jones Healthcare and Technology Innovation Conference
Location:	Las Vegas, NV
Date:	Wednesday, 9 April 2025
Time:	4:30 pm ET

The Citizens Life Sciences Conference
Location:	New York, NY
Date:	Thursday, 8 May 2025
Time:	1:00 pm ET

Jefferies Global Healthcare Conference
Location:	New York, NY
Date:	Wednesday & Thursday, 4 & 5 June 2025

Additional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors & Media section of Immutep’s website.

About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Catherine Strong, Sodali & Co.
+61 (0)406 759 268; catherine.strong@sodali.com

U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2524467908"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524467908\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524467908?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524467908","market":"us","top_or_hot":-1,"title":"Immutep to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/ZYF8BwxDMnxS4hNmrsTIFg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578\" title=\"new logo.jpg\" vspace=\"5\"/>\n<p><strong><strong>SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- </strong></strong> <a href=\"https://laohu8.com/S/IMMP\">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:</p>\n<table>\n<tbody>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Jones Healthcare and Technology Innovation Conference</strong></td>\n<td> </td>\n</tr>\n<tr>\n<td>Location:</td>\n<td>Las Vegas, NV</td>\n<td> </td>\n</tr>\n<tr>\n<td>Date:        </td>\n<td>Wednesday, 9 April 2025</td>\n<td> </td>\n</tr>\n<tr>\n<td>Time:</td>\n<td>4:30 pm ET</td>\n<td> </td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>The Citizens Life Sciences </strong><strong>Conference</strong></td>\n</tr>\n<tr>\n<td>Location:</td>\n<td>New York, NY</td>\n</tr>\n<tr>\n<td>Date:</td>\n<td>Thursday, 8 May 2025</td>\n</tr>\n<tr>\n<td>Time:</td>\n<td>1:00 pm ET</td>\n</tr>\n<tr>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Jefferies Global Healthcare Conference</strong></td>\n</tr>\n<tr>\n<td>Location: </td>\n<td>New York, NY</td>\n</tr>\n<tr>\n<td>Date:</td>\n<td>Wednesday &amp; Thursday, 4 &amp; 5 June 2025</td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p>Additional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors &amp; Media section of Immutep’s website.</p>\n<p><strong>About Immutep</strong><br/>Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.<br/></p>\n<p><strong>Australian Investors/Media:</strong><br/>Catherine Strong, Sodali &amp; Co.<br/>+61 (0)406 759 268; catherine.strong@sodali.com<br/><br/></p>\n<p><strong>U.S. Media:</strong><br/>Chris Basta, <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, Investor Relations and Corporate Communications<br/>+1 (631) 318 4000; chris.basta@immutep.com<br/><br/></p>\n<br/></body></html>","source":"yahoofinance_au","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep to Participate in Upcoming Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-04-02 20:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/ZYF8BwxDMnxS4hNmrsTIFg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578\" title=\"new logo.jpg\" vspace=\"5\"/>\n<p><strong><strong>SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- </strong></strong> <a href=\"https://laohu8.com/S/IMMP\">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:</p>\n<table>\n<tbody>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Jones Healthcare and Technology Innovation Conference</strong></td>\n<td> </td>\n</tr>\n<tr>\n<td>Location:</td>\n<td>Las Vegas, NV</td>\n<td> </td>\n</tr>\n<tr>\n<td>Date:        </td>\n<td>Wednesday, 9 April 2025</td>\n<td> </td>\n</tr>\n<tr>\n<td>Time:</td>\n<td>4:30 pm ET</td>\n<td> </td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>The Citizens Life Sciences </strong><strong>Conference</strong></td>\n</tr>\n<tr>\n<td>Location:</td>\n<td>New York, NY</td>\n</tr>\n<tr>\n<td>Date:</td>\n<td>Thursday, 8 May 2025</td>\n</tr>\n<tr>\n<td>Time:</td>\n<td>1:00 pm ET</td>\n</tr>\n<tr>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Jefferies Global Healthcare Conference</strong></td>\n</tr>\n<tr>\n<td>Location: </td>\n<td>New York, NY</td>\n</tr>\n<tr>\n<td>Date:</td>\n<td>Wednesday &amp; Thursday, 4 &amp; 5 June 2025</td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p>Additional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors &amp; Media section of Immutep’s website.</p>\n<p><strong>About Immutep</strong><br/>Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.<br/></p>\n<p><strong>Australian Investors/Media:</strong><br/>Catherine Strong, Sodali &amp; Co.<br/>+61 (0)406 759 268; catherine.strong@sodali.com<br/><br/></p>\n<p><strong>U.S. Media:</strong><br/>Chris Basta, <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, Investor Relations and Corporate Communications<br/>+1 (631) 318 4000; chris.basta@immutep.com<br/><br/></p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/immutep-participate-upcoming-investor-conferences-120000160.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/immutep-participate-upcoming-investor-conferences-120000160.html","article_id":"2524467908","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524467908","pubTimestamp":1743595200,"columns":[],"sourceInfo":{"source_id":"yahoofinance_au","name":"Yahoo Finance AU"},"weMediaInfo":null,"summary":"SYDNEY, AUSTRALIA , April 02, 2025  -- Immutep Limited  , a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:. Additional information for the Jefferies presentationwill be made available closer to the conference on theEvents pagewithin the Investors & Media section of Immutep’s website.About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 , and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.U.S. Media:","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Immutep将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":0.9,"IMMP":1},"content_text":"SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:\n\n\n\n \n \n\n\nJones Healthcare and Technology Innovation Conference\n \n\n\nLocation:\nLas Vegas, NV\n \n\n\nDate:        \nWednesday, 9 April 2025\n \n\n\nTime:\n4:30 pm ET\n \n\n\n \n \n \n\n\nThe Citizens Life Sciences Conference\n\n\nLocation:\nNew York, NY\n\n\nDate:\nThursday, 8 May 2025\n\n\nTime:\n1:00 pm ET\n\n\n \n\n\nJefferies Global Healthcare Conference\n\n\nLocation: \nNew York, NY\n\n\nDate:\nWednesday & Thursday, 4 & 5 June 2025\n\n\n \n \n\n\n\nAdditional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors & Media section of Immutep’s website.\nAbout ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.\nAustralian Investors/Media:Catherine Strong, Sodali & Co.+61 (0)406 759 268; catherine.strong@sodali.com\nU.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; chris.basta@immutep.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}